Recently, Zhejiang Langhua Pharmaceutical Co.,Ltd, announced that Dr.Mingda Bi was assigned as Vice President of Langhua Pharma. Dr. Bi is in charge of formulation development department and directly report to Dr. Ma Jianguo, CEO of Langhua Pharma. Dr. Bi will lead formulation development team to strengthen the development and manufacturing capability of various dosage form to meet customers’ all-round demand, helps Langhua to be the world-class CDMO company which provide customers both development and commercial manufacturing services.

Dr.Bi awarded Pharmacy PhD from Purdue University, USA, 2002. After graduation, he successively worked for Wyeth Pharmaceuticals (now Pfizer), Japan's Yamanochi Pharmaceuticals (now Astellas) and Amgen Pharmaceuticals in U.S. So far with more than 20 years successful career, Dr.Bi has rich practical experience in the research and development of dosage forms, and has a deep understanding and knowledge of global regulations, declarations, and ICH guidelines. 

Dr. Bi presided over the research and development of several marketed drugs such as Cinacalcet pediatric capsules, Lumarkras high-dose specifications, upcoming drugs such as Omecamtiv Mecarbil complex sustained-release tablets, clinical products such as Omecamtiv Mecarbil sustained-release microtablets, and more than 20 other pre-clinical and clinical innovative drugs.

Dr. Jianguo Ma, CEO of Langhua Pharmaceuticals, said: "Welcome Dr. Bi to join Langhua Pharmaceuticals. Dr. Bi has more than 20 years of experience in the development and application of innovative drug research and development for various stages, different routes, and different dosage forms, and Dr. Bi is professional in most advanced technology. At the same time, he has an international strategic vision. The joining of Dr. Bi will provide a strong impetus for the development of Langhua pharmaceutical formulation business, and provide our customers with better one-stop services from pre-clinical, clinical stage to commercial production."

Dr. Mingda Bi said: “Langhua Pharmaceuticals accumulates good experience and reputations in the field of CDMO. I strongly agree with Langhua’s strategic planning and vision. Langhua Pharmaceuticals is in a stage of rapid development and is investing resources to improve R&D capabilities and expand its technology platform. It is a very good opportunity to join Longhua. I am full of confidence in Longhua’s future, and I am looking forward to contributing to the one-stop CMC service of Langhua APIs and formulations together with the team, to help new drug research of Langhua’s partners.

About Formulation Development Department 
Langhua Formulation development department provides services for pre-clinical, clinical, and commercial end to end pharmaceutical dosage form development and manufacturing. Our purpose is to accelerate our partners New Chemical Entity (NCE) development from pre-clinical stage to marketing application authorization and commercial launch. We have rich experience of innovative drug development from concept to launch, and in-depth understanding of China, U.S. European regulation and ICH guideline. We use Fastlane concept and our rich project management experience to shorten the drug development time, to help our customer save development cost. 

About Langhua Pharma
Zhejiang Langhua Pharmaceutical Co., Ltd., the subsidiary of Viva Biotech Holding, is a leading company in the field of innovative drug discovery. As a fast-growing CDMO company, Langhua is committed to providing global innovative drug partners with an efficient, flexible and high-quality one-stop CMC (Chemistry, Production and Control) solutions for small molecule APIs and formulations from preclinical stage to commercialization. Langhua has three R&D centers in Shanghai, Taizhou and Ningbo. The R&D leaders in various fields are all returnees who have worked in MNCs for many years. They have rich experience in the process R&D, scale-up production and application of innovative drug raw materials and formulations. The production base, which is located in Taizhou, Zhejiang, has passed the site audit and inspection from different authorities like the US FDA,EDQM.